

SUMMER 2024

accelerator

THE NEXT LEAP **FORWARD**

Powering a new generation of
myeloma treatments and cures



MULTIPLE MYELOMA
Research Foundation

A MESSAGE FROM THE CEO



“Knowing that comprehensive, scalable research initiatives are the best way forward, we’ve continued to prioritize bold, innovative projects that only the MMRF can do.”

Dear friends,

For over 25 years, the Multiple Myeloma Research Foundation has worked relentlessly to accelerate a cure for every patient with multiple myeloma. Our persistence has yielded amazing results – patients today are more educated and empowered than ever, and life expectancies have tripled in the last two decades – but myeloma remains an incurable disease, and our work is far from finished.

This year, our organization has continued to move with urgency and speed in pursuit of multiple pathways to a cure. Knowing that comprehensive, scalable research initiatives are the best way forward, we’ve continued to prioritize bold, innovative projects that only the MMRF can do. We invest in early-stage biotechnology companies through the Myeloma Investment Fund®. We also have exciting new

initiatives set to launch, like the groundbreaking clinical research program HORIZON and the MMRF Virtual Lab®, an innovative data collaboration platform. The latest issue of *Accelerator* magazine highlights how these important projects and others are powering the next leap forward.

You’ll also read about our efforts to improve the patient and caregiver experience with best-in-class resources and support, empowering the community to

be stronger advocates for their own care. We recognize the many inequities that impact so many individuals with a myeloma diagnosis, and we will continue to fight until all patients benefit equally from the scientific and clinical advances we pursue.

No matter what challenges we encounter on the path to a cure, our determination will never waver. We are grateful for your support as we take these critical next steps toward a world free of multiple myeloma.

Michael Andreini, President and Chief Executive Officer, Multiple Myeloma Research Foundation®




Contents

A Message From the CEO	2	Myeloma Accelerator Challenge Program..	16
Our Strategic Approach	5	MMRF Research Fellows Award Program.....	17
Accelerating the Development of Novel Therapies.....	6	Empowering the Myeloma Community.....	18
MIF® Partner Profile: David de Graaf, PhD..	8	Health Equity Summit.....	22
Advancing Clinical Trials.....	9	MMRF Research Scholars Program	23
Driving Optimal and More Personalized Treatment Approaches	12	Donor Profile: Steven Boxer	24
The MMRF Virtual Lab®	15	2024 Fall Calendar of Events	25
		MMRF Leadership.....	26

Our Strategic Approach

The priorities in our strategic plan guide our work. The MMRF is building on our legacy and focusing on objectives to accelerate a cure for each and every myeloma patient.

Focusing on these strategic priorities will improve outcomes for all patients. Across each endeavor, we are committed to advancing diversity, equity, inclusion, and health equity.



- **1998**
First research foundation established solely for multiple myeloma
- **2004**
First myeloma clinical consortium
- **2008**
First myeloma genome sequenced
- **2018**
First myeloma platform drug trial
- **2024**
MMRF reaches \$600 million in funds raised for myeloma research

Progress is important. Cures are essential.

Making headway in the urgent fight against myeloma motivates us every day. Despite leading meaningful progress for patients for more than two decades, our organization is squarely focused on what lies ahead: exponential change and monumental outcomes for patients.

Partner with us as we power a new generation of myeloma treatments and cures. Donate today.



Accelerating

the Development of Novel Therapies



With more than 15 new treatments since we opened our doors, including CAR T-cell therapy and other immunotherapies that have led to longer remissions and better quality of life, we have made incredible progress. But today, nearly all multiple myeloma patients relapse. Until there is a cure for every myeloma patient, we will continue our urgent work to advance the next generation of treatments to improve outcomes.

The Myeloma Investment Fund®

The Myeloma Investment Fund® (MIF®) is the first and only mission-driven venture philanthropy fund focused on accelerating a cure for myeloma. We identify and invest in the most promising biotechnology companies with innovative clinical solution assets and technologies that could be transformative for myeloma patients. This task largely falls to early-stage, venture-backed biotech companies that take on a disproportionate amount of scientific and financial risk that can only be overcome with world-class expertise and reliable funding. This fund is supported entirely by philanthropy and all financial returns are reinvested until there is a cure for every patient.

A summary of our recent investments:

Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company's broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X mental retardation protein (FMRP) and a diversified pipeline of promising oncology assets.

Dynamic Cell Therapies (DCT) is a preclinical biotech company founded out of the Dana-Farber Cancer Institute with two platforms to improve



and prolong the efficacy of CART therapies. The company has generated promising results in both in vitro and in vivo multiple myeloma models.

Envisagenics is an AI-driven biotechnology company founded in 2014 as a spinout from the Cold Spring Harbor Laboratory that harnesses the therapeutic potential of RNA splicing.

Leveraging an extensive map of over 14 million RNA splicing events, Envisagenics' SpliceCore platform enables the discovery of disease-specific targets, paving the way for the rational design and development of RNA therapeutics and immunotherapies.

Nammi Therapeutics, Inc. is an immunotherapy company developing first-in-class products for the treatment of cancer. Nammi's next-generation masked immunocytokines are tumor antigen-targeting antibodies fused to a cytokine which delivers direct anti-tumor killing capability as well as immune response-initiating activity and inhibits systemic immune activation due to its masking technology.

IMPACT
OF MIF®
(Since 2019)

~\$22M
Committed

17
Companies
in Portfolio

6
Treatments
Advanced
to the Clinic



David de Graaf, PhD

David de Graaf, PhD, is the Co-founder and CEO of Reverb Therapeutics. Stephanie Oestreich, PhD, MPA, Managing Director of the MMRF's Myeloma Investment Fund®, recently spoke with David about Reverb's innovative approach to myeloma, its relationship with the MIF®, and how the MMRF's strategic partnership with early-stage biotechnology companies can help fuel potentially transformative opportunities for patients.

Tell us a little bit about Reverb's exciting science and approach to myeloma.

I've been very lucky to have had the chance to make drugs for people who need them, and I'd say the idea for Reverb really started when I saw the suffering of people with myeloma. We often think of this as an area that has been solved — there's been so much progress — but patients are still out there and they're in need of better solutions.

One of the ideas we had was to make use of the properties of the human body to heal itself, and we think ultimately this could lead to a cure. We thought about these molecules called cytokines, which are the signaling molecules of the immune system. They tell immune cells to expand or become more cytotoxic, meaning that they can kill tumor cells. Rather than try to take these cytokines and engineer them into drugs, which is very difficult, we wanted to use drugs to pick them up in blood where they circulate already and concentrate them near the cancer cells. So that's the concept behind

Reverb — to let the signal of the immune system reverberate much longer.

The MIF® was founded by the MMRF five years ago because there were simply not enough biotech companies with exciting ideas being funded. Beyond investment, how will Reverb's partnership with the MIF® continue to help accelerate cures?

There's a huge sense of comfort because of the credibility that the MMRF brings and the valuable resources you provide that other investors can't. We recently met with your Chief Medical Officer and Chief Scientific Officer; they are world-class experts, physician-scientists, who understand the fundamentals of what we're doing and how to move this into the clinic and how clinical trials would look. How would we ever get this expertise except through a relationship like this?

What motivates you as a leader to do this critical work, and what gives you hope?

Like the MMRF, I feel personally responsible for making sure that these therapies we're now developing are becoming a reality and will get to patients with multiple myeloma. In many ways, building a company is a team sport, and the MMRF and the MIF® are part of our team now, so I just wanted to say thank you to not only the MMRF and the MIF®, but also to the patients for their time and for the focus that they have and for the capital that they provide in order to develop these therapies.



Watch the full conversation between Stephanie and David on the MMRF's YouTube channel [here](#).



Advancing Clinical Trials

We support a portfolio of innovative clinical trials that aim to identify optimal treatment strategies and improve outcomes, particularly for patients with the highest unmet clinical need.

One of the most promising is our HORIZON Clinical Platform Trials Program, which was specifically designed to determine the best combination, sequence, and duration of therapy for patients at every stage of the disease. The HORIZON Clinical Platform Trials Program is a new

kind of clinical trial known as an adaptive platform trial. Adaptive platform trials evaluate several therapies simultaneously, reducing the time it takes to bring new treatment to patients.

Importantly, the HORIZON Clinical Platform Trials Program builds on our commitment to ensure that our research initiatives are racially diverse, representative of the patient population, and inclusive of experiences that have not historically been reflected in research.



MAKE A LASTING IMPACT AT THE MMRF.

Your legacy can shape the future. Contact Pam Lewis at 832-372-4009 or visit themmrf.giftplans.org to learn more about how you can make a meaningful, lasting difference. Together, we can help achieve a world free of myeloma.



“Throughout my eight-year journey with multiple myeloma, the MMRF has been a consistent source of support and information. Their patient navigators and informative sessions have been invaluable. I give to the MMRF because I am confident that they are working hard on the research that will find a cure and encourage everyone to support the MMRF in any way possible.”

— Jeff Vollaro, Legacy Society member, living with myeloma since 2016

Learn more about the different gift options that will help make a lasting impact at the MMRF today. Visit themmrf.giftplans.org or scan the QR code at right.



HORIZON Clinical Platform Trials

In 2024, the MMRF is launching the groundbreaking HORIZON Clinical Platform Trials Program. We expect to begin enrolling patients into the relapsed/refractory trial before the end of 2024. The high-risk/newly diagnosed trial is planned to launch in the first half of 2025.

Testing more pathways to a cure

The adaptive nature of the trials allows investigators to test multiple treatment approaches in parallel, generating faster answers about which treatments work best.

Expanding clinical trial eligibility

The MMRF is dedicated to making the HORIZON

trials as accessible and inclusive as possible to be representative of the real-world US patient population. This approach includes, but is not limited to, a diversity plan; having an outside diversity officer; offering financial assistance for travel, lodging, and more where needed; and expanding the eligibility criteria to allow patients who are typically excluded to be included.

HORIZON, through its design and multi-institutional cooperation, is set up to answer research questions that other types of trials lack the capabilities to pursue.

Individual Academic / Research Center Trials	HORIZON Clinical Platform Trials Program	Biopharma / Corporate Trials
<ul style="list-style-type: none"> • Single trial without a control group • Small, biased sample size • Takes a long time 	<ul style="list-style-type: none"> • Randomized trials with a control group • Large, representative sample size • Quick, efficient start-up time 	<ul style="list-style-type: none"> • Randomized trials with a control group • Large sample size (may not be representative) • Takes a long time • High cost
<p>Low impact for decision-making and clinical practice</p>	<p>High impact for treatment development and clinical practice</p>	<p>High impact for treatment development only</p>

“When I was first introduced to the HORIZON clinical trial concept, I was on board immediately. It is a truly unique platform as it allows us to test multiple new treatment strategies in a timely manner, significantly reducing the time it would take to obtain results. The benefit it offers myeloma patients cannot be emphasized enough.”

—Cindy Varga, MD, Atrium Health Levine Cancer Institute, MMRC® Steering Committee member and HORIZON Investigator

Driving

Optimal and More Personalized Treatment Approaches



Multiple myeloma is not one disease, but many — each driven by different biological features. This means no two myeloma patient experiences are the same, and every myeloma patient will respond differently to therapies. More research is needed to deepen our understanding of this complex cancer so we can determine the best treatment plan for each individual patient.

Data Initiatives Update

Through our groundbreaking MMRF CoMMpassSM Study, we have built the largest molecular and clinical dataset — from more than 1,100 patients — in the public domain of myeloma, yielding incredible insights to drive progress in research and patient care. Additionally, to develop a more comprehensive picture of myeloma disease biology, the MMRF has built upon CoMMpassSM by generating new data on myeloma patients' immune systems through our Immune Atlas research program.

The MMRF currently possesses over 500 TB — roughly the equivalent of a 500-year-long music playlist — of genomic, clinical, and immune data, with more data being generated through new studies and collaborations as researchers and partners continue to analyze myeloma biology, clinical response, and relapse.

Translational Research Umbrella (TRU) Program

The MMRF CoMMpassSM Study and the MMRF

“Lack of collaboration or lack of data access significantly hinders progress. Sharing is essential for the scientific process. There’s no time for delays in getting large data sets across a disease like multiple myeloma.”


—George Mulligan, PhD, Chief Scientific Officer, Multiple Myeloma Research Foundation

Immune Atlas generated landmark findings that changed the way we understand and treat myeloma.

The MMRF's new Translational Research Umbrella (TRU) Program builds upon these legacy programs to help us understand which patients respond to specific therapies — and which do not — and why.

Leveraging the most cutting-edge technologies available, the MMRF TRU Program will answer important questions, particularly those surrounding newer therapies: *Which patients do/do not benefit from CAR T and bispecific treatments? What are the clinical and biological characteristics of patients who relapse from four-drug regimens? For early relapse patients, what are the results of different second-line options?*






The MMRF Virtual Lab[®]

A critical barrier to medical research and scientific discovery is a lack of access to high-quality data. Due to competition for funding and publication, most scientific data are siloed and academic researchers are not incentivized to share data outside of their institution. The MMRF, however, is and always has been committed to both generating and sharing our datasets widely to drive collaboration and accelerate treatments. We ensure that myeloma researchers all over the world, no matter their affiliation, have access to a wealth of robust data from thousands of myeloma patients to power their work.

The MMRF Virtual Lab[®] (VLab) aggregates and harmonizes the data from all of the MMRF's landmark research projects in a single, proprietary platform. It equips academic and biopharma researchers with free online tools to view data from thousands of patients and run detailed analyses. Powered by Amazon Web Services and other partners, VLab also enables artificial intelligence and machine learning techniques while protecting patient privacy and data security.

Through VLab, researchers are required to share their analyses so that we can continue to build



the body of knowledge about this disease while also fostering a community of experts working together to accelerate a cure.

VLab aggregates and harmonizes the data from all our landmark research projects, including CoMMpassSM, in a single, proprietary platform.

MYELOMA ACCELERATOR CHALLENGE PROGRAM

The MMRF continues its support of multicenter translational research projects through our Myeloma Accelerator Challenge (MAC) Program. With MAC, we have identified the highest areas of unmet need and selected the best researchers around the world to work together to more accurately define what it means to be high-risk and determine the best treatment options for those patients. Through these projects, researchers are sharing resources and samples to advance compelling hypotheses that are ready for rapid testing in clinical trials. Over the course of three years, we are investing \$21 million in research for high-risk newly diagnosed multiple myeloma and high-risk smoldering myeloma.

2023 MAC Program Recipients



Samir Parekh, MD
Icahn School of Medicine at Mount

Sinai, New York, NY
Transforming Treatment of High-Risk Myeloma

Collaborating institutions:

- Albert Einstein College of Medicine
- Hackensack University Medical Center
- Stanford University Medical Center
- University of California, San Francisco
- Washington University in St. Louis



Sagar Lonial, MD
Emory Winship Cancer Center, Atlanta, GA

Clinical & Multi-Omics Platforms to Define HR SMM

Collaborating institutions:

- Dana-Farber Cancer Institute
- Atrium Health Levine Cancer Institute
- Icahn School of Medicine at Mount Sinai
- Massachusetts General Hospital
- Mayo Clinic
- Memorial Sloan Kettering Cancer Institute



Pieter Sonneveld, MD, PhD
Erasmus University

Medical Center, Rotterdam, Netherlands

A Systems Biology Approach to High-Risk Multiple Myeloma

Collaborating institutions:

- Amsterdam University Medical Centers
- Julius Maximilian University of Würzburg
- University of Turin
- University of Salamanca

“Thanks to organizations like the MMRF and efforts like CoMMpassSM and Immune Atlas, we are going to fill in the map of myeloma and get diagnostics that will give us a better understanding of patients, the tumor, and the clinical behavior.”

—Samir Parekh, MD, Icahn School of Medicine at Mount Sinai

MMRF RESEARCH FELLOWS AWARD PROGRAM

One of our longest-running and most impactful programs, the MMRF Research Fellows Award Program is an initiative supporting young researchers at the postdoctorate, medical fellow, or junior faculty levels working under the supervision or guidance of a research mentor in the myeloma field. We have supported young researchers with more than 150 awards since our inception, creating a steady pipeline of new researchers, many of whom later credit the MMRF with helping to establish their first lab or focus on an important new area of science. These \$150,000, two-year grants change the trajectory of researchers’ careers and infuse the field of myeloma research with fresh perspectives and cutting-edge training.

2023 MMRF Research Fellows



Luis Corchete Sánchez, PhD
Postdoctoral Fellow, Massachusetts General Hospital, MA
Role of Sex Chromosomes in Multiple Myeloma




Ioannis Kostopoulos, PhD
Senior Postdoctoral Fellow, National and Kapodistrian University of Athens, Greece
Bone Marrow Microenvironment During the Natural History of Multiple Myeloma



Marcella Kaddoura, MD
Assistant Professor, Miller School of Medicine at University of Miami, FL
Defining the Genomic Landscape of Myeloma with CCND1:IGH Translocation



Enze Liu, PhD
Assistant Professor, Indiana University, IN
Utilizing Long-Read Technology to Study Splicing and M6A as a Whole



Holly Lee, MD
Resident, University of Calgary, Canada
Oncogenic Dependencies of Anti-BCMA Therapy Resistant Multiple Myeloma



James Nyamataga, MD
Instructor, Muhimbili University of Health and Allied Sciences, Tanzania
Molecular Characterization of Multiple Myeloma in Tanzania

Empowering


the Myeloma Community



We arm myeloma patients and their families, as well as their healthcare providers, with the tools and resources they need to improve their care and extend their lives, with a focus on reaching historically underserved patient populations. Our

programs and partnerships with the myeloma clinical and research community meet patients where they are to advance more equitable access to information and care to drive better outcomes for every patient.

Annually, our 25 education programs reach over 16,000 participants, which is more than any other organization. Patient responses after seeking information or participating in a program:



They are also sharing their successes:

“The MMRF enables us to have more in-depth conversations with the doctors, such as requesting tests, pain management, and meeting with an orthopedic surgeon for compression fractures instead of being told what to do.”

— Myeloma Patient Caregiver, Florida

“My disease has not progressed since 2016, so I use these seminars to better understand the illness and to keep up-to-date with treatment should the need arise.”

— Myeloma Patient, Texas

Supporting Every Patient for the Best Outcome

Our high-quality patient education programming includes in-person, interactive events around the United States featuring myeloma specialists, educational summits, patient toolkits, informational brochures and webinars, and a podcast called *Myeloma Matters* that spotlights myeloma patients and their disease journey.

Patient Navigation Center

The MMRF Patient Navigation Center (PNC) is a unique service that enables myeloma patients and caregivers to connect with patient navigators, all of whom previously worked as oncology nurses, for guidance and support throughout their journey. MMRF Patient navigators answer questions, share resources, and help keep patients on the right path. We've seen evidence that the more knowledgeable patients and caregivers are about myeloma, the more empowered they are to make the decisions and choices that lead to improved care.

In a three-month follow-up after working with one or more of the MMRF Patient Navigators:

- 91% of respondents agreed that communicating with the PNC about their condition reduced their anxiety.
- 85% of respondents agreed that after communicating with the PNC they understood how to better manage their myeloma.

Community Engagement and Activation

In 2023, the MMRF launched a new initiative to raise awareness about myeloma and educate communities at high risk of developing myeloma — particularly in the Black community, which makes up 20% of myeloma patients — about the signs and symptoms and how to get the best care. Additionally, the MMRF continues to build partnerships, engage organizations that are socially active and trusted within the Black community, institute direct-to-patient outreach with community members and leaders, and provide financial and logistical support to enable broader access to clinical trial participation.



Our first two community summits took place in Atlanta and Philadelphia.

“The Atlanta Community Summit bridged crucial gaps in multiple myeloma knowledge, fostering a supportive environment for better health outcomes through powerful speakers and storytelling. By partnering with local community-based organizations, the MMRF educated attendees about multiple myeloma while also building trust within the Black community, empowering individuals through education, support, and unity in the fight against multiple myeloma.”

—Rachel Soloman, Associate Director, US Public Affairs and Patient Advocacy in Oncology, Sanofi Pharmaceuticals

MMRF Multiple Myeloma Community Summits

In partnership with Acclinate, a healthcare organization focused on connecting with communities of color to improve clinical trial diversity, the MMRF has begun hosting community events in metro areas around the country. The primary focus of these events is to build awareness and community rather than direct education or action.

The MMRF has already hosted successful events in Atlanta and Philadelphia, spreading awareness at a regional level by engaging with BIPOC communities, organizations, and partners. We also have future events in the works for Detroit and Birmingham.





Group photo from the 2023 Health Equity Summit

Health Equity Summit

The MMRF's annual Health Equity Summit brings together the entire myeloma ecosystem — policymakers, academic researchers, biopharma executives, retail pharmacists, and community health advocates — to identify strategies and solutions to drive greater inclusivity in and access to clinical research studies in multiple myeloma. We know certain patient populations are often excluded from cancer clinical trials and the benefits of potentially efficacious therapies.

2024 Summit

The upcoming 2024 Health Equity Summit will be the MMRF's third to date. Building on the success of the 2023 summit, we will continue to work toward measurable progress around equity and inclusivity by identifying solutions in select, targeted patient populations. This year, we will concentrate on addressing the challenges and circumstances most prevalent among Latinx, Asian/Pacific Islander, and Indigenous populations; rural populations; women of childbearing age; and older adults. Additionally, we will be looking ahead to examine the importance of considering health equity and community participation as AI becomes more prevalent in identifying patients for clinical trial participation.

“The most important thing that I think we’re doing is changing the dialogue. We’re empowering the communities. We’re starting with the community. We’re asking them what is it that they’re struggling with, what are the issues that they would like for us to address from a scientific perspective? And it’s a crucial change in mindset.”

—Yvens Laborde, MD, Ochsner Health

As always, addressing inequities in myeloma clinical research is intrinsic to the MMRF's goal of ensuring every person with myeloma receives optimized treatment and eventually a cure. The MMRF is taking action to integrate key learnings shared at the summits into its research strategy. Learn more about our commitment to diversity, equity, and inclusion by visiting themmrf.org/about/diversity-equity-inclusion.

Coming Soon

The MMRF will soon publish an assessment of the role that laboratory reference ranges, or the data norms used to evaluate study participants, play as barriers to clinical trial participation, while also proposing tangible steps to improve the enrollment of a diverse and representative population. Biological differences, laboratory criteria around blood, and more lead to the exclusion of certain racial and ethnic groups — particularly Black patients — from vital clinical trials based on outdated thresholds that are perpetuated by institutional racism in the healthcare system. As a direct result, the MMRF is working to adopt broader inclusion criteria and less-restrictive exclusion criteria for all of our clinical trials.

“I’ve been working with the MMRF for maybe a decade ... They have been at the cutting edge of bringing research, the best drugs, and potential cures for myeloma to the world. They’ve helped in drug development, drug implementation, and approval. Now they want to bring that to a wider community. They want to bring that to the people that other people have forgotten about. The older patients, the patients of ethnicities and races that had been previously ignored by clinical trials. They want to bring that to everyone.”

—Craig Cole, MD, Karmanos Cancer Center

MMRF RESEARCH SCHOLARS PROGRAM

We launched the MMRF Research Scholars Program in 2023 to provide financial and mentorship support for Black researchers and clinicians (MD and/or PhD) who are currently active or interested in pursuing a career in the field of myeloma. Awardees are provided up to \$400,000 over four years to support their career development as researchers from postdoctoral to first tenure-track positions. To further the growth of talented early-career researchers, the program also provides a Scholars Mentoring Committee for review of project conduct and advice on career development, strategic collaboration matching, guidance on research protocol development, translational research, core technologies, and tissue banks.

The 2023 MMRF Research Scholars Award recipients are featured below. Stay tuned for the 2024 cohort announcement coming soon.

Inaugural MMRF Research Scholars Award Recipients



Joselle Cook, MD, MBBS
Mayo Clinic
*Prevalence of MGUS
Among Unique Populations
of Black People*



Eden Biltibo, MD, MS
Vanderbilt University
Medical Center
*Identifying Effective and Cost-Conscious
Maintenance Daratumumab Dosing*

DONOR PROFILE

Steven Boxer

Steven Boxer, a long-time supporter of the MMRF, is a 73-year-old myeloma patient from New York. He's a retired restaurateur, having owned restaurants both in New York City and throughout the country. He received CAR T-cell therapy in June 2024.



I discovered it on my 65th birthday in January 2016. I was getting dressed to go to the restaurant and I bent over to tie my shoes and I just couldn't get up. I couldn't breathe. It turned out that I had a compression fracture on my vertebrae and my ribs were pushing into my lungs. And that was the beginning of the worst year of my life. I started breaking bones and was injured constantly. When my feet hit the floor in the morning I saw stars. It was six months before I finally got on a treatment that strengthened my bones, but thankfully we discovered it early and I've been very receptive to the treatments.


My son-in-law and friends of his family know Tom Brokaw, and they sent me a signed copy of his book (*A Lucky Life Interrupted: A Memoir of Hope* about his

personal battle with multiple myeloma). I read it, and it really was inspiring to me. Their support and Tom's book showed me that this is not the end of everything and you can work your way through it.

The MMRF has been very influential in giving me information through their database, recommendations, and answers to a lot of questions. I really believe in giving support and vital information to anyone who doesn't know where to go, doesn't know what to ask, doesn't know what they've got, etc. My introduction to the MMRF and their wealth of information pretty much saved my life.

My family has a foundation that was set up by my parents about 30 years ago. We give annually to the MMRF, the research being conducted by my doctors and others who have treated my family, different hospitals, and more. I know that, already, the MMRF shares all of their data with every scientist and researcher who is out there. Simply continuing to do that alone would be invaluable. I think it's incredible that all of these researchers have a big database that they can go to for answers, and you can't express the value and the importance of that.


I still have a lot of pain. I have had four types of treatments since 2016 that have worked well, but then they stop working. This is why the MMRF is accelerating new treatments to find one that works for every patient. I've had some phenomenal doctors and wonderful teams. I'm hoping (with the CAR T-cell therapy) that I can start to have a semi-normal life where I can at least get away for a while and not have to worry about medical visits.



Steven and his family on vacation

2024 Fall Calendar of Events

MMRF PATIENT EDUCATION & COMMUNITY EVENTS		
September 11	Newly Diagnosed MM: Where to Begin	Webinar
September 27	Community Summit	Detroit
September 30	Smoldering Myeloma	Podcast
October 9	IMS Highlights	Expert Session
November 7	Navigating Clinical Studies	Webinar
November 14	Patient Summit	Tampa
November 14	Community Summit	Birmingham
November 16	Patient Summit	Seattle
December 3	Understanding BCMA-Targeted Therapies	Webinar
December 19	ASH Highlights	Expert Session
MMRF WALK/RUN EVENTS		
September 8	Montrose Harbor, Grove 16	Chicago
September 14	Phalen Regional Park	St. Paul
September 14	DCR Mother's Rest at Carson Beach	Boston
September 21	Milliken State Park, Detroit Riverwalk	Detroit
September 28	National Harbor, 155 National Plaza	Oxon Hill, MD
October 5	Hudson River Park, Pier 76	New York City
October 19	Fairmount Park	Philadelphia
October 26	Westside Park	Atlanta
November 2	ZooTampa at Lowry Park	Tampa
November 16	Ferris Wheel Park Green	Dallas
November 23	The Water Works in Buffalo Bayou Park	Houston
December 7	Scottsdale Stadium	Scottsdale, AZ
December 14	Virtual	Virtual
MMRF ENDURANCE EVENTS		
Sept. 28–Oct. 8	MM4MM Mount Kilimanjaro	Tanzania
September 29	Berlin Marathon	Berlin, Germany
October 13	Chicago Marathon	Chicago
November 3	New York City Marathon	New York City
December 1–7	MM4MM Guatemala: 3-Volcano Challenge	Guatemala



Thank you to our 2024 Road to Victories sponsor, Johnson & Johnson!
The six-day adventure during the final week in August will bring cyclists on a stunning ride through California Wine Country to raise funds for myeloma research. Let's keep pedaling toward a cure!

Multiple Myeloma Research Foundation

383 Main Avenue, 7th Floor, Norwalk, CT 06851

Phone: 203-229-0464

Fax: 203-972-1259

Email: info@themmr.org

Web: TheMMRF.org



BOARD OF DIRECTORS

Kathy Giusti, MBA
Founder, MMRF

David L. Lucchino
Lori Tauber Marcus

Karen E. Andrews
Founder, MMRF

Hugh Martin

Thomas Conheaney
Chairman

Susan Marvin

William S. McKiernan

Gerald McDougall
Vice Chairman

Mike Mortimer

David R. Parkinson, MD

Kenneth Anderson, MD
Rodney Gilmore

Marie Pinizzotto, MD, MBA

Adrian Rosenkranz

Steven Shak, MD

Kimberly A. White

EXECUTIVE LEADERSHIP TEAM

Michael Andreini
President & CEO

Pam Lewis
Vice President,
Development & Events

Anne Quinn Young, MPH
Chief Mission Officer

Greg Rubenstein
Vice President,
Marketing & Communications

Hearn Jay Cho, MD, PhD
Chief Medical Officer

Christopher Williams
Vice President,
Business Development

Karen Dietz, JD, MBA
Chief Administrative Officer,
General Counsel

Katie Wozniak
Vice President,
Clinical Research

George Mulligan, PhD
Chief Scientific Officer

Francesca LaRosa
Senior Director,
Human Resources

Stephanie Oestreich,
PhD, MPA
Managing Director,
Myeloma Investment Fund®

HONORARY BOARD

Dusty Baker

Sugar Ray Leonard

James T. Brown

Tara Lipinski

Bob Costas

Wynton Marsalis

Katie Couric

Marlee Matlin

Cindy Crawford

Eric McCormack

Ann Curry

Deborah Norville

Clive J. Davis

Sharon Osbourne

CeeLo Green

Gary Pettis

Scott Hamilton

Carl Quintanilla

Mariska Hargitay

Al Roker

Lou Holtz

Sage Steele

Bonnie Hunt

Brian Williams

Senator Kay Bailey Hutchison

Pat Williams

Dan Jansen

Bob Woodruff

Diana Krall

Lee Woodruff

Meet Pam Lewis, the MMRF's new VP of Development & Events



Pam joined the MMRF in March of 2024 and brings over 20 years of development and corporate sales experience focused on healthcare and disease advocacy. In this new role, Pam will expand the MMRF's financial resource development and generate community relationships.

What drew you to the MMRF? My mom was diagnosed in 2006, and information from the MMRF led to her being successfully treated. This role allows me to be more directly involved.

What have you learned in your first six months as a part of this team and community? The MMRF team and community is warm, smart, dedicated, passionate, and full of action. This community boldly rises to the challenge every day.

What have you found is different about the MMRF than other organizations you've worked with in the health space? The MMRF has an unmatched level of professionalism, accountability, and commitment to measurable strategy. Unlike others, our job is to put ourselves out of business — we are that devoted to this community.

What is it about events and community building that you find so important? Magic happens when people come together in community to share triumphs, heartbreaks, and hope. We celebrate and honor each other, tell stories, and hold heart space for the day every patient has a cure.

Looking for guidance?

The MMRF is here to help. The professionals at our Patient Navigation Center can offer insights, counseling, and support throughout your treatment journey.

Give us a call, Mon.–Fri., 9am–7pm ET
888-841-6673

or email us at PatientNavigator@TheMMRF.org

FROM THE WAITING ROOM...



...TO YOUR LIVING ROOM

A guide to every stage of the cancer experience.



STAY INFORMED

Subscribe today for home and office delivery.
curetoday.com/subscribe

cure[®]
curetoday.com



About the MMRF

The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has raised over \$600 million for research, opened nearly 100 clinical trials, and helped bring to market 15+ FDA-approved therapies that have tripled the life expectancy of myeloma patients. To learn more, visit themmrf.org.

